InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) EPS (Diluted) : $-3.29 (TTM As of Sep. 2023)

View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings EPS (Diluted)?

InVivo Therapeutics Holdings's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.87. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.29.

InVivo Therapeutics Holdings's EPS (Basic) for the three months ended in Sep. 2023 was $-0.87. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.29.

InVivo Therapeutics Holdings's EPS without NRI for the three months ended in Sep. 2023 was $-0.87. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.29.

During the past 3 years, the average EPS without NRIGrowth Rate was 79.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 80.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, InVivo Therapeutics Holdings's highest 3-Year average EPS without NRI Growth Rate was 86.70% per year. The lowest was -746.70% per year. And the median was 29.50% per year.

InVivo Therapeutics Holdings EPS (Diluted) Historical Data

The historical data trend for InVivo Therapeutics Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings EPS (Diluted) Chart

InVivo Therapeutics Holdings Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Diluted)

Get a 7-Day Free Trial

-3,520.25

-882.00

-32.75

-7.48

-6.83

InVivo Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Diluted)	Get a 7-Day Free Trial															-1.98	-0.95	-0.85	-0.62	-0.87

Competitive Comparison of InVivo Therapeutics Holdings's EPS (Diluted)

For the Biotechnology subindustry, InVivo Therapeutics Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InVivo Therapeutics Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's PE Ratio falls into.

InVivo Therapeutics Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

InVivo Therapeutics Holdings's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-10.49	-	0)	/	1.536
	=	-6.83

InVivo Therapeutics Holdings's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-2.697	-	0)	/	3.106
	=	-0.87

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.29

InVivo Therapeutics Holdings (OTCPK:NVIVQ) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

InVivo Therapeutics Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

04I:Germany

Address

One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.invivotherapeutics.com

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

Executives

Brice Foose	10 percent owner	236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak	director	C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison	director	ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli	director, officer: CEO and CMO	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher	officer: Chief Financial Officer	C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield	director
Bob Rosenthal	director	20 NEWBURY ST, BOSTON MA 02116
Heather Hamel	officer: Chief Legal Officer and GC	ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino	officer: See Remarks	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty	officer: Chief Financial Officer	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz	officer: Interim CFO	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield	director	11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl	officer: Chief Commercial Officer	ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne	officer: Chief Medical Officer	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070